Qiagen bumps up Cellestis offer

Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) increased its proposal to acquire Australian diagnostics company Cellestis Ltd. (ASX:CST) to A$3.80 per share, or about A$359 million (US$374 million) in cash. The new price is 7% above the original A$3.55 per share offer that Qiagen proposed in April. Cellestis' board recommends shareholders vote in favor of the offer at a meeting slated for the end of July (see BioCentury Extra, April 4). ...